Amongst candidate COVID-19 inflammation biomarkers is IRF5 itself, raising the possibility of studying this key molecule across the whole range of SARS-CoV-2 infection and associated comorbidities (124, 125); already IRF5 is suggested as a novel adipose marker in chronic metabolic inflammation (108) and inflammatory bowel disease (125). The gene discussed is IRF5; the disease is inflammatory bowel disease.